Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAIR Platform Study in Advanced or Metastatic Non-Small Cell Lung Cancer
jRCT2031250529Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised trial of rilvegostomig in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Started Jan 2026; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250529.